Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318731 | 1.00 | KMT2A (0.64) | KMT2ACES2CES1MEN1PTGS1 | |
| SCHEMBL319987 | 1.00 | KMT2A (0.64) | KMT2ACES2CES1MEN1PTGS1 | |
| SCHEMBL1428029 | 0.89 | KMT2A (0.52) | KMT2ACES2CES1PTGS2ALDH1A1 | |
| SCHEMBL1565875 | 0.86 | MAPK1 (0.51) | KMT2ACES2CES1PTGS1ALDH1A1 | |
| SCHEMBL13522785 | 0.84 | KMT2A (0.51) | KMT2ACES2CES1MEN1PTGS1 | |
| SCHEMBL9000507 | 0.82 | PTGS1 (0.59) | KMT2AMEN1PTGS1PTGS2 | |
| SCHEMBL8881032 | 0.82 | ESR1 (0.54) | KMT2APTGS1ALDH1A1LMNASLC6A3 | |
| SCHEMBL4776154 | 0.82 | L3MBTL1 (0.45) | KMT2AALDH1A1LMNA | |
| SCHEMBL1564938 | 0.82 | CYP1A2 (0.50) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL4013605 | 0.82 | L3MBTL1 (0.46) | KMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 907 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954994-A | Method for free radical polymerization based on macro-micro reactor | 南京工业大学 | 2025-05-09 | — | — | CN | claimed |
| CN-118459631-A | Photo-thermal double-switch controllable free radical polymerization method based on quaternary ammonium salt in-situ initiation | 苏州大学 | 2024-08-09 | — | — | CN | claimed |
| CN-116003682-B | Acrylonitrile copolymer and preparation method and application thereof | 山西钢科碳材料有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-116003682-A | Acrylonitrile copolymer and preparation method and application thereof | 山西钢科碳材料有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-115286583-A | Diphenylaminopyrimidine-containing compound, preparation and application thereof as HDACs enzyme inhibitor | 山东大学 | 2022-11-04 | — | — | CN | claimed |
| CN-113061205-B | Controllable free radical polymerization method based on C-N bond breakage | 苏州大学 | 2022-03-11 | — | — | CN | claimed |
| CN-113061205-A | Controllable free radical polymerization method based on C-N bond breakage | 苏州大学 | 2021-07-02 | — | — | CN | claimed |
| US-20190106590-A1 | COATING COMPOSITION CONTAINING A SORBIC ACID ESTER AND A PHOTOCATALYST | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-04-11 | — | — | US | claimed |
| EP-3440141-A1 | COATING COMPOSITION CONTAINING SORBIC ACID ESTER AND PHOTOCATALYST | Dow Global Technologies, LLC (US) | 2019-02-13 | — | — | EP | claimed |
| WO-2017173646-A1 | COATING COMPOSITION CONTAINING SORBIC ACID ESTER AND PHOTOCATALYST | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-10-12 | — | — | WO | claimed |
| WO-2003011917-A1 | METHOD OF CURING ELASTOMERS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3773573-B1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-4206120-A | Oxaazabicycloheptane antibiotics | BEECHAM GROUP LIMITED (GB) | 1980-06-03 | — | — | US | disclosed |
| EP-0010398-A1 | Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-30 | — | — | EP | disclosed |
| US-4166863-A | ACTIVE AGAINST HEMOPHILUS AND NEISSERIA | BEECHAM GROUP LIMITED (GB) | 1979-09-04 | — | — | US | disclosed |
| US-4102901-A | MONIC ACID ESTERS | BEECHAM GROUP LIMITED (GB) | 1978-07-25 | — | — | US | disclosed |
| US-4046759-A | INTERMEDIATES FOR CEPHALOSPORINS | ISHIMARU TOSHIYASU | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB3, ERBB2 | KMT2A 2644/4885CES2 2480/4885CES1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.